3 Committee discussion

The appraisal committee considered evidence from a number of sources. See the committee papers for full details of the evidence.

Clinical pathway

People with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia will welcome a new treatment option

3.1 The clinical experts stated that the aim of treatment is to lower, and reduce long-term exposure to, low-density lipoprotein cholesterol (LDL-C) and that statins are the first treatment offered. The clinical experts explained that if people's LDL-C levels remain too high, then ezetimibe may also be offered and, if they are eligible, alirocumab and evolocumab are also options. The patient expert explained that people with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia are at increased risk of cardiovascular events and that the conditions are treated inconsistently across the NHS. They highlighted that it can be difficult to access testing for high cholesterol and that treatments like alirocumab and evolocumab are only offered to people with higher levels of LDL-C. They added that a large proportion of people who are eligible for these treatments are not referred to secondary care to have them. The clinical and patient experts also highlighted that many people do not receive testing for heterozygous familial hypercholesterolaemia. The patient expert stated that inclisiran offers a twice-yearly treatment option, compared with more frequent dosing of currently available treatments, and this would likely increase treatment adherence. The clinical experts explained that it is difficult to reach LDL-C target levels with currently available oral treatments (statins and ezetimibe). The committee concluded that people with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia would welcome a new treatment option.

The appropriate position of inclisiran in the treatment pathway is after maximum tolerated statins alone or with ezetimibe

3.2 The NICE scope outlined 3 separate positions for inclisiran in the treatment pathway:

  • compared with maximum tolerated statins

  • when maximum tolerated statins do not appropriately control LDL-C, and

  • when maximum tolerated statins with ezetimibe do not appropriately control LDL-C.

    The NICE scope also requested analyses for when statins are contraindicated or not tolerated. The company positioned inclisiran as a treatment option if LDL-C levels were too high after standard of care treatment. The company defined standard of care as a mix of maximum tolerated statins and other lipid-lowering therapy, including a small proportion of ezetimibe use based on the ORION trials (see section 3.5 and section 3.7). The clinical experts stated that inclisiran could be used after maximum tolerated statins, or after maximum tolerated statins and ezetimibe. The committee noted that this was in line with the treatment pathway defined by inclisiran's marketing authorisation, which allows its use after maximum tolerated statins or maximum tolerated statins and other lipid-lowering therapies. The committee concluded that the appropriate position of inclisiran in the treatment pathway is after maximum tolerated statins or after maximum tolerated statins with ezetimibe.

Inclisiran is likely to be used in a primary care setting

3.3 The company proposes that inclisiran would be given by a healthcare professional in a primary care setting. After an initial dose, it would be given again after 3 months and then twice a year. The committee was aware that other currently available treatments, such as alirocumab and evolocumab, are usually prescribed in secondary care. The clinical experts stated that the primary care setting could be appropriate, although it would need some changes in how the condition is currently managed. The committee noted that, in general, the responses to technical engagement from professional organisations supported the use of inclisiran in a primary care setting. These responses also noted that primary care can be used to identify and provide treatment for people who would be eligible for inclisiran. The committee noted that there were some concerns in submissions received surrounding the implementation of inclisiran in a primary care setting but noted that the Accelerated Access Collaborative and NHS England had plans to support the implementation of inclisiran within a primary care setting. The committee was also aware of an ongoing implementation research project (SPIRIT) that aims to assess the feasibility of delivering inclisiran within a primary care setting in England. The committee noted that this trial was due to complete in 2022 and considered that it could provide some relevant information on how inclisiran can be delivered in a primary care setting. The committee accepted that inclisiran is likely to be used in a primary care setting.

Population

The populations included in the company's submission are clinically relevant but are narrower than inclisiran's marketing authorisation and trial data

3.4 The marketing authorisation for inclisiran does not specify a minimum LDL-C level before beginning treatment. The company presented analysis by 3 populations:

  • Secondary prevention: people who have had a previous cardiovascular event, including acute coronary syndrome (such as myocardial infarction or unstable angina requiring hospitalisation), coronary or other arterial revascularisation procedures, coronary heart disease, ischaemic stroke or peripheral arterial disease. The committee noted that NICE's technology appraisal guidance on alirocumab and evolocumab defined this population as having a high risk of cardiovascular disease.

  • Primary prevention with elevated risk: people who have not had a cardiovascular event and have type 2 diabetes or heterozygous familial hypercholesterolaemia, or who have a 10-year cardiovascular disease risk of 20% or more based on Framingham risk score or equivalent.

  • Primary prevention with heterozygous familial hypercholesterolaemia.

    In each of the 3 populations, the company submitted evidence based on a minimum LDL-C level of 2.6 mmol/l. This was narrower than the marketing authorisation in all 3 populations and narrower than the clinical trial data for the secondary prevention population (see section 3.7). The company stated that a minimum LDL-C level of 2.6 mmol/l was selected because a greater clinical benefit was observed in the ODYSSEY OUTCOMES trial (alirocumab compared with placebo after acute coronary syndrome) in people with a baseline LDL-C of 2.6 mmol/l or more. The company also highlighted that an LDL-C of 2.6 mmol/l was close to the mean baseline LDL-C in the ORION clinical trials and the company's clinical experts supported the use of this threshold. The clinical experts at the meeting highlighted that the use of a 2.6 mmol/l threshold meant that inclisiran, if approved, would enable more people to access a treatment that could significantly reduce LDL-C levels, meaning that they were more likely to reach LDL‑C goals. The clinical experts noted that the ORION-11 trial used a 10-year cardiovascular disease risk of 20% or higher, based on Framingham risk score or equivalent, as part of its criteria for the primary prevention with elevated risk population. They explained that NHS practice uses the QRISK score to identify risk and this measure would be used instead and adjusted to identify this population. The evidence review group (ERG) highlighted that a lack of genetic testing for all people with suspected heterozygous familial hypercholesterolaemia may result in cases either being missed or being incorrectly classified as other population groups (see section 3.1). The committee concluded that the populations included in the company's submission are clinically relevant but are narrower than inclisiran's marketing authorisation and the clinical trial data.

Comparators

The appropriate comparators are ezetimibe, alirocumab, evolocumab and maximum tolerated statins

3.5 NICE technology appraisal guidance recommends ezetimibe, alirocumab and evolocumab as treatment options in the same part of the treatment pathway as inclisiran (see section 3.2). The company did not consider ezetimibe to be a relevant comparator. Instead, the company included a small amount of ezetimibe use as part of standard of care, based on the ORION clinical trial programme (see section 3.7), and did not include the efficacy of ezetimibe as estimated by the network meta-analysis (NMA; see section 3.8). The company highlighted that ezetimibe use in the NHS was low and that NICE's guideline on cardiovascular disease: risk assessment and reduction includes ezetimibe only as an option and not a required pathway step before further treatment. The ERG believed that ezetimibe should be a distinct comparator and their base case used the efficacy from the company's NMA for ezetimibe, rather than comparing with the company's definition of standard of care, which was assumed to provide no reduction in baseline LDL-C (see section 3.2). The ERG had been informed by its clinical experts that if LDL-C is too high after maximum tolerated statins, then there is a clinical decision to either switch to rosuvastatin (another statin, which is not yet generic) or add ezetimibe. The ERG also highlighted that, unlike for treatment with alirocumab or evolocumab, there are no minimum LDL-C thresholds needed for treatment with ezetimibe (see section 3.6). It also noted that ezetimibe is now available as a generic treatment, which means its cost is low, and highlighted that ezetimibe was considered a relevant comparator in each of NICE's previous technology appraisals in this condition. The ERG also highlighted that hypercholesterolemia is undertreated, and this applies to all treatments. The committee agreed with the ERG that ezetimibe should be considered as a relevant comparator. The committee also agreed that it would not eliminate the company's definition of standard of care from its decision-making, noting that this was a mix of predominately maximum tolerated statins, with low amounts of ezetimibe use (but did not include the efficacy of ezetimibe as estimated by the NMA), as in the ORION trials. The committee concluded that the appropriate comparators are ezetimibe, alirocumab, evolocumab and maximum tolerated statins (when inclisiran is given in combination with statins).

The relevant comparators are dependent on alirocumab or evolocumab eligibility

3.6 The committee noted that the populations in the company submission included people with a minimum LDL-C level of 2.6 mmol/l (see section 3.4). Therefore, a proportion of people would be eligible for alirocumab or evolocumab based on recommendations in NICE's technology appraisal guidance on alirocumab and evolocumab. This includes people in:

  • secondary prevention, if their LDL-C levels are persistently above 4 mmol/l and they have a high risk of cardiovascular disease, defined as any history of:

    • acute coronary syndrome (such as myocardial infarction or unstable angina requiring hospitalisation)

    • coronary or other arterial revascularisation procedures

    • coronary heart disease

    • ischaemic stroke

    • peripheral arterial disease

  • secondary prevention who have a very high risk for cardiovascular disease (defined as recurrent cardiovascular events or cardiovascular events in more than one vascular bed [that is, polyvascular disease]), only if LDL-C levels are persistently above 3.5 mmol/l

  • secondary prevention with heterozygous familial hypercholesterolaemia, only if LDL-C levels are persistently above 3.5 mmol/l, and

  • primary prevention with heterozygous familial hypercholesterolaemia, only if LDL-C levels are persistently above 5 mmol/l.

    The committee was also aware that there are populations in the company's submission who would not be eligible for alirocumab or evolocumab as outlined by previous NICE recommendations, specifically people in:

  • secondary prevention who have a high risk for cardiovascular disease and an LDL-C level between 2.6 mmol/l and 4.0 mmol/l

  • secondary prevention who have a very high risk for cardiovascular disease and an LDL-C level between 2.6 mmol/l and 3.5 mmol/l

  • secondary prevention with heterozygous familial hypercholesterolaemia and an LDL-C level between 2.6 mmol/l and 3.5 mmol/l

  • primary prevention with elevated risk (excluding heterozygous familial hypercholesterolaemia) with an LDL-C level of 2.6 mmol/l or more

  • primary prevention with heterozygous familial hypercholesterolaemia and an LDL-C level between 2.6 mmol/l and 5.0 mmol/l.

    The committee noted that, based on NICE's technology appraisal guidance on ezetimibe, ezetimibe was available as an option in all populations and also a relevant comparator in all populations included in the company's submission (see section 3.4 and section 3.5). The committee considered that for people who are ineligible for alirocumab or evolocumab, ezetimibe was the only relevant NICE-recommended comparator. But, it acknowledged that maximum tolerated statins was also a treatment option and a relevant comparator in this population (see section 3.5). For people who are eligible for alirocumab or evolocumab, the committee agreed that ezetimibe, alirocumab, evolocumab and maximum tolerated statins are relevant comparators. The committee were aware that mean baseline LDL-C would be lower in the population ineligible for alirocumab or evolocumab compared with people who are eligible. The committee concluded that the relevant comparators are dependent on alirocumab or evolocumab eligibility.

Clinical evidence

Results from ORION-9, ORION-10 and ORION-11 show inclisiran reduces LDL-C levels and are generalisable to people with primary hypercholesterolaemia or mixed dyslipidaemia in the NHS

3.7 The clinical trial evidence in the company submission came from 3 randomised 18-month trials comparing inclisiran with placebo:

  • ORION-9 included people with heterozygous familial hypercholesterolaemia and elevated LDL-C levels (2.6 mmol/l or more)

  • ORION-10 included people with atherosclerotic cardiovascular disease (secondary prevention) and elevated LDL-C levels (1.8 mmol/l or more)

  • ORION-11 included people with atherosclerotic cardiovascular disease (secondary prevention) and elevated LDL-C levels (1.8 mmol/l or more) and people who had not had a cardiovascular event (primary prevention) but had elevated risks of atherosclerotic cardiovascular disease and LDL-C levels (2.6 mmol/l or more).

    The trials included people on lipid-lowering therapies (such as statins or ezetimibe or both). The ERG noted that the proportion of people in the ORION trials receiving ezetimibe was 51% in ORION-9, 11% in ORION-10 and 9% in ORION-11. In the trials, people who were on a statin were on their maximum tolerated dose. The trials also included people who had documented evidence of statin intolerance. All 3 trials had co-primary endpoints of mean LDL-C percentage change from baseline to 510 days and time-adjusted LDL-C percentage change by day 90 and up to day 540. The results showed that inclisiran compared with placebo significantly reduced levels of LDL-C. From baseline to day 510, LDL-C was reduced by 47.9% (95% confidence interval [CI] 53.5 to 42.3), 52.3% (95% CI 55.7 to 48.8) and 49.9% (95% CI 53.1 to 46.6) in ORION-9, ORION-10 and ORION-11 respectively. Similar results were also seen in the co-primary end point of time-adjusted LDL-C percentage change from day 90 to day 540. The committee was aware that the clinical trials were mostly carried out in the US but noted that the clinical expert submissions stated that the trial results were generalisable to the NHS. The clinical trial results also showed that rates of adverse events were similar for people treated with inclisiran compared with placebo, with the exception of injection site reactions, which were more common in people treated with inclisiran (8.2% compared with 1.8% in those treated with placebo). The committee concluded that results from ORION-9, ORION-10 and ORION-11 show that inclisiran reduces LDL-C levels compared with placebo and these results are generalisable to people with primary hypercholesterolaemia or mixed dyslipidaemia seen in NHS clinical practice.

Indirect treatment comparison

The network meta-analyses used by the company are appropriate but are associated with some uncertainties

3.8 Because the ORION trials only included a placebo comparator, the company undertook NMAs to indirectly compare inclisiran with alirocumab, evolocumab and ezetimibe. The company produced 3 NMAs for different populations, based on a common placebo comparator:

  • secondary prevention or primary prevention with elevated risk on maximum tolerated statins

  • secondary prevention or primary prevention with elevated risk and statin intolerance

  • heterozygous familial hypercholesterolaemia on maximum tolerated statins.

    The company used a 24-week timepoint in its NMAs. The company explained that this choice reflected the longest available timepoint for which data was available from comparator treatment trials included in the NMAs. The results from the random-effects model showed that inclisiran was associated with a greater LDL-C reduction compared with ezetimibe and compared with placebo. The NMAs estimated that inclisiran was associated with an LDL-C reduction that was marginally less than with alirocumab or evolocumab, although this result was not statistically significant. The company explained that it could not provide effectiveness estimates for ezetimibe in the heterozygous familial hypercholesterolaemia on maximum tolerated statins NMA, as no trials were identified for ezetimibe in that population. The ERG agreed that the methods used by the company to undertake the NMA were appropriate. But they noted that the NMAs included trials with high levels of heterogeneity and that some trials in the NMAs were inconsistent in their definitions of cardiovascular risks. The committee noted that the 24-week timepoint used in the NMA added some uncertainty to the clinical outcomes as there was limited evidence of whether LDL-C reduction achieved at 24 weeks would be maintained over a lifetime, as assumed in the model (see section 3.10). The committee was also aware that the estimates from the NMA were more favourable for inclisiran than the co-primary endpoints from the clinical trials. The committee concluded that the network meta-analyses used by the company are appropriate but are associated with some uncertainties.

Long-term treatment effect of inclisiran

The effect of inclisiran on cardiovascular event risk is uncertain as there is a lack of long-term evidence

3.9 The completed ORION clinical trials (see section 3.7) were unable to provide enough data on the effectiveness of inclisiran in reducing cardiovascular events and mortality. This was because the follow up of 18 months was not long enough to provide these outcomes. The company used the reduction in LDL-C from the indirect treatment comparison (see section 3.8) to estimate the assumed reduction in cardiovascular events. The company used the Cholesterol Treatment Trialist Collaboration (CTT) meta-analyses, which reported change in cardiovascular event risk per 1 mmol/l reduction in LDL-C by statin use. The ERG agreed that these analyses were appropriate and noted that earlier versions of this source were used in past NICE technology appraisals in this disease area (NICE technology appraisal guidance on ezetimibe, alirocumab, evolocumab and bempedoic acid with ezetimibe). The committee expressed a concern that the link between changes in LDL-C levels and cardiovascular outcomes used in the company model, may not be appropriate for inclisiran because the mechanism of action is different to that of statins. The clinical experts stated that the CTT meta-analyses were appropriate and that a similar relationship between LDL-C lowering and a reduction in cardiovascular event risk as seen with statin use could be expected with inclisiran. The committee was aware that longer-term trial evidence was available for alirocumab (ODYSSEY OUTCOMES) and evolocumab (FOURIER) but noted that the follow-up period of these trials may not have been long enough to estimate the full effect on cardiovascular outcomes. The committee also noted that the ODYSSEY OUTCOMES trial was restricted to people who had had a recent cardiovascular event. The committee was also aware that an ongoing UK clinical trial, ORION-4, would provide outcome data on cardiovascular events with a median follow up of 5 years for inclisiran compared with placebo in people who have already had a cardiovascular event. The committee noted, however, that this trial would not report until 2026. The company explained that a global clinical trial with a similar design was in development. The company also confirmed that it is planning a clinical trial (ORION‑17) to collect data on cardiovascular outcomes of inclisiran compared with placebo, in people who have not experienced a cardiovascular event. The committee considered that the lack of data on inclisiran's effect on cardiovascular outcomes was a key uncertainty in the appraisal and was a major driver of the cost-effectiveness results. The committee concluded that the effect of inclisiran on cardiovascular event risk is uncertain as there is a lack of long-term evidence.

The assumptions of no treatment effect waning, and no treatment discontinuation may be appropriate but adds uncertainty

3.10 The company's economic model assumed that the treatment effect as estimated by the NMA at 24 weeks (see section 3.8) would be maintained at the same level over a lifetime. The company stated that this assumption was based on previous NICE technology appraisals of alirocumab and evolocumab in the same condition. The ERG noted that given the lack of long-term trial evidence beyond 18 months to support this assumption, the company could have provided a scenario in which inclisiran's effectiveness is assumed to reduce over time. The clinical experts stated that inclisiran would likely be used over the course of a lifetime, as LDL-C levels would be expected to return to baseline if discontinued. The company highlighted that the assumption of no treatment discontinuation was also based on previous NICE technology appraisals of alirocumab and evolocumab and stated that the treatment discontinuation rate for inclisiran in the ORION clinical trials was low (annual discontinuation rate of 1.7% in ORION-9 and 3.2% in ORION-10 and ORION-11). The committee noted that there was a lack of long-term data for inclisiran to support this assumption. The committee concluded that assumptions of no waning of treatment effect and no treatment discontinuation may be appropriate but add uncertainty.

Innovation

Inclisiran is innovative, however all relevant benefits are likely to be captured in the quality-adjusted life year calculations

3.11 The company highlighted that inclisiran was the first cholesterol-lowering small interfering RNA (siRNA) and has the potential to be a step change in how the condition is managed. The company, clinical and patient experts highlighted that treatment with inclisiran had the potential to increase treatment adherence, because of its twice-yearly dosing schedule (see section 3.1). The committee considered the potential additional benefits inclisiran might provide but concluded that there was no evidence of additional gains in health-related quality of life over those already included in the quality-adjusted life year (QALY) calculations. The committee concluded that inclisiran is innovative, however all relevant benefits are likely to be captured in the QALY calculations.

Cost-effectiveness estimates

The ERG's base case includes the committee's preferred assumptions

3.12 The ERG's base-case analyses included ezetimibe as a separate comparator and also included comparisons with maximum tolerated statins. Therefore, it differed from the company's base case, which included a small amount of ezetimibe use as part of standard care (see section 3.5). The committee was aware that the ERG's base-case analyses was otherwise the same as the company's. This included using the company's NMA estimate for treatment efficacy (see section 3.8) and no treatment waning or treatment discontinuation (see section 3.10). The committee concluded that it preferred the ERG base case but would take the company analyses into account in its decision making.

Because of the uncertainty the acceptable incremental cost-effectiveness ratios are £20,000 per QALY gained and above £30,000 per QALY lost

3.13 NICE's guide to the methods of technology appraisal notes that above a most plausible incremental cost-effectiveness ratio (ICER) of £20,000 per QALY gained, judgements about the acceptability of a technology as an effective use of NHS resources will take into account the degree of certainty around the ICER. The committee will be more cautious about recommending a technology if it is less certain about the ICERs presented. The committee also needs to be increasingly certain of the cost effectiveness of a technology as the impact of its adoption on NHS resources increases and may need more robust evidence for technologies that are expected to have a larger impact. Therefore, because of the high level of uncertainty in the clinical and economic evidence, primarily caused by the lack of outcome data on inclisiran's effect on cardiovascular events (see section 3.9), the NMA clinical effectiveness estimates (see section 3.8) and long-term treatment effects and discontinuation assumptions (see section 3.10), the committee agreed that an acceptable ICER would be no higher than £20,000 per QALY gained or above £30,000 per QALY lost when considering each of the population groups and their respective LDL-C ranges (see section 3.6).

Inclisiran is cost effective for secondary prevention in people who are eligible for alirocumab and evolocumab

3.14 The cost-effectiveness results for the secondary prevention population who are eligible for alirocumab or evolocumab were assessed by calculating net monetary benefit. This was because inclisiran was estimated to provide marginally fewer incremental QALYs compared with alirocumab or evolocumab (see section 3.8). The incremental net monetary benefit of inclisiran was compared with alirocumab or evolocumab, at threshold values of £30,000 saved per QALY lost using the committee preferred assumptions (see section 3.12 and section 3.13). This resulted in a positive incremental net monetary benefit at that threshold value, meaning that the amount of lost QALYs associated with inclisiran compared with alirocumab or evolocumab was acceptable when considering the differences in costs between these treatments. The committee considered that net monetary benefit was appropriate for decision making as it was likely that any differences in QALYs between inclisiran and alirocumab or evolocumab are small. This confirmed that inclisiran is cost effective compared with alirocumab and evolocumab in the following secondary prevention populations in which alirocumab and evolocumab are available:

  • secondary prevention with a high risk for cardiovascular disease, only if LDL-C levels are persistently above 4 mmol/l

  • secondary prevention with a very high risk for cardiovascular disease, only if LDL-C levels are persistently above 3.5 mmol/l

  • secondary prevention with heterozygous familial hypercholesterolaemia, only if LDL-C levels are persistently above 3.5 mmol/l.

    Inclisiran was associated with an ICER of below £20,000 per QALY gained compared with either ezetimibe or maximum tolerated statins in the populations eligible for treatment with alirocumab and evolocumab described above. The committee concluded that inclisiran is cost effective in these populations for both pairwise and fully incremental analysis. Because of the confidential discount for inclisiran, the exact ICERs have not been reported here.

Inclisiran is cost effective for secondary prevention in people who are not eligible for alirocumab or evolocumab

3.15 Using the committee's preferred assumptions (see section 3.12) the most plausible ICERs for inclisiran compared with ezetimibe or maximum tolerated statins for the secondary prevention population who are not eligible for alirocumab or evolocumab (see section 3.6), were likely to be around or below £20,000 per QALY gained in pairwise and fully incremental analysis. Therefore, the committee concluded that inclisiran is cost effective in this population. Because of the confidential discount for inclisiran, the exact ICERs cannot be reported here.

Inclisiran is not cost effective in the primary prevention population with elevated risk

3.16 Using the committee's preferred assumptions (see section 3.12) the most plausible ICERs for inclisiran in the primary prevention with elevated risk population and an LDL-C of at least 2.6 mmol/l, were likely to be above £20,000 per QALY gained. This was based on considering comparisons with ezetimibe or maximum tolerated statins in pairwise and fully incremental analysis. Therefore, the committee concluded that inclisiran is not cost effective in the primary prevention population with elevated risk.

Inclisiran is not cost effective in the primary prevention with heterozygous familial hypercholesterolaemia population

3.18 Using the committee's preferred assumptions (see section 3.12) the most plausible ICERs for the primary prevention with heterozygous familial hypercholesterolaemia populations were as follows:

  • In people who are not eligible for alirocumab or evolocumab (LDL-C levels between 2.6 mmol/l and 5 mmol/l; see section 3.6) the ICERs were significantly above £20,000 per QALY gained when compared with maximum tolerated statins.

  • In people who are eligible for alirocumab or evolocumab (LDL-C levels of at least 5 mmol/l; see section 3.6), the ICER was below £20,000 per QALY gained when compared with maximum tolerated statins. The incremental net monetary benefit of inclisiran was compared with alirocumab or evolocumab, at threshold values of £30,000 saved per QALY lost (see section 3.13) in this population. This resulted in a positive incremental net monetary benefit for inclisiran compared with these treatments.

    The committee noted that the company did not provide cost-effectiveness results for inclisiran compared with ezetimibe in the heterozygous familial hypercholesterolaemia populations. Comparisons with ezetimibe were part of the committee's preferred base case (see section 3.12). This was because there was no clinical trial data for ezetimibe in these populations to inform the NMA (see section 3.8). For the alirocumab- or evolocumab-eligible and -ineligible populations, the committee considered that the ICERs for inclisiran compared with ezetimibe would be higher than the ICERs comparing inclisiran with maximum tolerated statins and would be significantly above £20,000 per QALY gained if incorporated into a pairwise and fully incremental analyses. The committee concluded that inclisiran is not cost effective in the primary prevention with heterozygous familial hypercholesterolaemia population.

Other factors

There are no equalities issues that can be addressed in this appraisal

3.20 A number of potential equality issues were raised during the appraisal. These included the higher prevalence of cardiovascular conditions in more deprived areas and in some specific populations (such as minority ethnic groups or people with severe mental health conditions or learning disabilities). The committee also heard that the treatments provided could vary across the NHS depending on region and availability of specialist care, and that there may be difficulties in accessing treatment for older people. The committee concluded that its recommendations for inclisiran would apply to all patients and that the recommendation would not affect people protected by the equality legislation any differently. The committee also considered that further evidence should be collected to assess whether the implementation of inclisiran into the treatment pathway would reduce health inequalities in this condition (see section 5.4).

Conclusion